Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Cybin to host fiscal Q2 results call Nov. 13

By The Northwire Desk — AI Analysis Nov 06, 2025 · 16:20 HELP · 8.63 Cybin Inc
HELP · Price

Executive Summary

  • Cybin Inc. will report its financial results for the second quarter ended September 30, 2025, and provide a business update.
  • The results and update will be presented via a conference call and webcast scheduled for Thursday, November 13, 2025, at 8 a.m. ET.
  • The company is currently advancing its pipeline, including the Phase 3 study of CYB003 for major depressive disorder and the Phase 2 study of CYB004 for generalized anxiety disorder.

Key Details

  • Reporting Period: Second Quarter 2025 (ended September 30, 2025).
  • Event Date: November 13, 2025.
  • Event Time: 8:00 a.m. Eastern Time.
  • Dial-in Numbers:
    • U.S. Toll Free: 800-245-3047
    • International: 203-518-9765
  • Conference ID: CYBN1113
  • Webcast Access: Archived webcast available on the company's investor relations website under the events and presentations page.
  • Pipeline Context:
    • CYB003: Proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder; received FDA Breakthrough Therapy designation.
    • CYB004: Proprietary deuterated N,N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.
    • Other: Research pipeline of investigational, 5-HT-receptor focused compounds.

Notable Quotes

  • No direct quotes from management were included in the provided text.
Read the original news release →

More from Cybin Inc

Jun 29, 2026 · 07:40

Helus Pharma burns cash faster in Phase 3 ramp but secures $50M runway as HLP003 nears topline readout

Earnings Jun 25, 2026 · 19:03

Helus Pharma closes $50M equity offering to fund Phase 3 MDD readout in Q4 2026, extending cash runway amid leadership transition.

Financings Jun 24, 2026 · 06:01

Helus Pharma(TM) Announces US$50 Million Underwritten Offering

Financings Jun 24, 2026 · 06:00

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

Regulatory Apr 28, 2026 · 07:30

Leadership Transition and Recruitment Partnership

M&A / Property Apr 20, 2026 · 08:15

Management Instability Clouds Near-Term Catalysts Despite Strong Cash Position

Regulatory